Question-and-Answer Session the potential that we [Audio Gap] time, right? And so -- and we see significant runway for that. I'd say in oncology, and I'll actually have Roopal speak to CEO & Chairman of the Board Like I think what you're seeing is a continuation of the strategy where we've talked about a quick return to growth. We exceeded our peak sales last year, just 2 years after the U.S. HUMIRA LOE with, I'd say, like 4 really like strong growth drivers for the company. Immunology, clearly, I mean, SKY ...